225Ac标记DOTA化huCC49抗体靶向TAG-72的卵巢癌α放射免疫治疗
该研究在卵巢癌小鼠模型中,用α发射体225Ac标记DOTA化huCC49抗体靶向TAG-72阳性移植瘤。放射免疫治疗以剂量依赖方式显著抑制肿瘤生长,7.4 kBq剂量使生存期较未治疗对照延长3倍以上;多次治疗方案(总5.4 kBq)也使生存期延长近3倍且无明显脱靶毒性。结论提示抗体靶向α放射治疗对卵巢癌具有潜力。
要点
- 225Ac标记huCC49抗体可剂量依赖地抑制卵巢癌移植瘤生长。
- 7.4 kBq单次剂量使生存期较未治疗对照延长3倍以上。
- 多次给药方案总5.4 kBq使生存期延长近3倍且无明显脱靶毒性。
核心结论
- 结果确立了抗体靶向α放射治疗用于卵巢癌的潜力,并可能推广至其他实体瘤的α放射免疫治疗。
研究设计与样本
- 在卵巢癌小鼠模型中,将DOTA化huCC49用α发射体225Ac标记,靶向TAG-72阳性移植瘤。
主要发现
- 225Ac标记DOTA化huCC49放射免疫治疗以剂量依赖方式显著降低肿瘤生长(1.85、3.7和7.4 kBq)。
- 7.4 kBq剂量使生存期较未治疗对照延长3倍以上。
- 多次治疗方案(1.85 kBq后每周0.70 kBq共5次,总计5.4 kBq)使生存期较未治疗对照延长近3倍,且无明显脱靶毒性。
关键数值与推荐
- 单次给药剂量分别为1.85、3.7和7.4 kBq。
- 多次治疗方案为1.85 kBq后每周0.70 kBq共5次,总计5.4 kBq。
临床怎么用
- 提示α放射免疫治疗可作为卵巢癌及其他实体瘤的潜在治疗策略,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioimmunotherapy, an approach using radiolabeled antibodies, has had minimal success in the clinic with several β-emitting radionuclides for the treatment of ovarian cancer. Alternatively, radioimmunotherapy with α-emitters offers the advantage of depositing much higher energy over shorter distances but was thought to be inappropriate for the treatment of solid tumors, for which antibody penetration is limited to a few cell diameters around the vascular system. However, the deposition of high-energy α-emitters to tumor markers adjacent to a typical leaky tumor vascular system may have large antitumor effects at the tumor vascular level, and their reduced penetration in normal tissue would be expected to lower off-target toxicity. Methods: To evaluate this concept, DOTAylated-huCC49 was labeled with the α-emitter 225Ac to target tumor-associated glycoprotein 72-positive xenografts in a murine model of ovarian cancer. Results:225Ac-labeled DOTAylated-huCC49 radioimmunotherapy significantly reduced tumor growth in a dose-dependent manner (1.85, 3.7, and 7.4 kBq), with the 7.4-kBq dose extending survival by more than 3-fold compared with the untreated control. Additionally, a multitreatment regime (1.85 kBq followed by 5 weekly doses of 0.70 kBq for a total of 5.4 kBq) extended survival almost 3-fold compared with the untreated control group, without significant off-target toxicity. Conclusion: These results establish the potential for antibody-targeted α-radionuclide therapy for ovarian cancer, which may be generalized to α-radioimmunotherapy in other solid tumors.
引用
- Minnix M, Li L, Yazaki PJ, et al. TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody. J Nucl Med. 2020. PMID: 32620701. doi:10.2967/jnumed.120.243394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。